Asia Pacific Preclinical Cro Market Size & Outlook
Asia Pacific preclinical cro market, 2018-2030 (US$M)
Related Markets
Asia Pacific preclinical cro market highlights
- The Asia Pacific preclinical cro market generated a revenue of USD 912.7 million in 2023.
- The market is expected to grow at a CAGR of 10.7% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 912.7 million |
| Market revenue in 2030 | USD 1,865.2 million |
| Growth rate | 10.7% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 16.0% of the global preclinical cro market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,865.2 million by 2030.
Toxicology testing was the largest segment with a revenue share of 22.55% in 2023. Horizon Databook has segmented the Asia Pacific preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The changing business model of MNC outsourcing and the rising cost of R&D is expected to increase preclinical outsourcing in Asia Pacific owing to cost efficiency offered by CROs in countries such as India and China. Established companies located in Western Europe and the U.S. pursue analytical services, site research development, and clinical activities in the Asia Pacific region.
The establishment of several CROs across the Asia Pacific region has also strengthened the preclinical trial outsourcing market in this region. For instance, Singapore has several CROs to support the growing needs of pharmaceutical and biopharmaceutical companies. Some of these CROs include IQVIA and ICON, which manage regional preclinical and clinical trials from Singapore.
Growth in the market is due to the advanced healthcare infrastructure in the region. Moreover, an increasing number of CROs are focusing on partnerships and investments. Likewise, the development of outsourcing hubs, the expansion of market players along with the availability of skilled practitioners further contribute to the growth of the market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific preclinical cro market size, by country, 2018-2030 (US$M)
Asia Pacific Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
